πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 20 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12427173

Use of bacteria, bacterial products, and other immunoregulatory entities in combination wi

Biomed Valley Discoveries, Inc. Β· Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12338269

IL-2 superagonists in combination with anti-PD-1 antibodies

Medicenna Therapeutics Inc. Β· Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12053534

Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12054556

Anti-PD-L1 antibody and use thereof

Oricell Therapeutics Co., Ltd. Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12054557

Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11993655

Anti-PD-L1 antibody and use thereof

Oricell Therapeutics Co., Ltd. Β· Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11926668

Anti-PD-1 antibodies for treatment of lung cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566076

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

Five Prime Therapeutics, Inc. Β· Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11542312

IL-2 superagonists in combination with anti-PD-1 antibodies

Medicenna Therapeutics Inc. Β· Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11421034

Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

Five Prime Therapeutics, Inc. Β· Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11324822

Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

Syndax Pharmaceuticals, Inc. Β· Granted Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11292842

Anti-PD-1 antibodies for treatment of lung cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11254746

Anti-PD-1 monoclonal antibody, and preparation method therefor and application thereof

SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11254752

Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibo

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10822414

Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using an

Sutro Biopharma, Inc. Β· Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10786552

Il-2RΞ²-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 anti

Nektar Therapeutics Β· Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10744116

Detection and treatment of anti-PD-1 therapy resistant metastatic melanomas

The Regents of the University of California Β· Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10736976

Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10683347

Treatment of cancer using anti-TGF-Ξ² and anti-PD-1 antibodies

The Regents of the University of California Β· Granted Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10010587

IL-2RΞ²-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 anti

Nektar Therapeutics Β· Granted Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted